View Post

Rare Patient Voice: Study Opportunity for Multiple Cancer Types

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: Cancer patients with any of the following cancer types: Breast Prostate Skin (Melanoma and Basal Cell) Bladder Kidney Lung 60 min Online Bulletin Board US patients only Compensation $100 Please sign up at the link below for more information or to see if you qualify. http://letlife.in/rare-patient-voice Why Sign up with Rare Patient Voice? Who knows better than you …

View Post

Rare Patient Voice: Bladder Cancer – Canadian Residents

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 60 min Web-Assisted Phone Interview Compensation $100 Please sign up at the link below for more information or to see if you qualify. https://rarepatientvoice.com/LetLifeHappen/ Why Sign up with Rare Patient Voice? Who knows better than you about your journey and experiences?  We connect you with researchers who are developing products and services which can help you and others …

View Post

Genetic Ancestry Linked to Differences in Molecular Features of Cancers

In In The News by Barbara Jacoby

By: Staff Reporter From: genomeweb.com People of different ancestral backgrounds can have different DNA methylation, mRNA, and microRNA expression levels, which in turn may affect how cancer manifests in patients from different populations and influence how it is treated, a new study has found. Using data from The Cancer Genome Atlas, researchers from the Broad Institute and elsewhere examined ancestry-mediated …

View Post

FDA Panel Supports Pembrolizumab for High-Risk NMIBC

In Clinical Studies News by Barbara Jacoby

By: Jason M. Broderick From: onclive.com The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 9 to 4 supporting the approval of a new drug application (NDA) for pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)–unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumors who are ineligible for or chose to …

View Post

Immunotherapy Added to CT Might Just Work in Bladder Cancer

In Clinical Studies News by Barbara Jacoby

By: Alexander M. Castellino, PhD From: medscape.com Immunotherapy added to chemotherapy might just work in advanced bladder cancer: results so far from IMvigor130 show an improvement in progression-free survival (PFS), but the data for overall survival (OS) are immature. Immunotherapy with atezolizumab (Tecentriq, Roche/Genentech) in combination with chemotherapy (CT) achieved a statistically longer median PFS of 8.2 months compared with …

View Post

Clinical drug trials network for Tennesseans shows promise

In Clinical Studies News by Barbara Jacoby

By: Jason Bolton From: bizjournals.com Tennesseans’ opportunities to access clinical trial drugs are more limited than other parts of the country. But, a year-old initiative out of a local university is getting the state’s residents enrolled in early drug and medical device access. “This network meets a huge need for University of Tennessee Health Science Center (UTHSC) clinical research,” said …

View Post

New Patient Resource from NCCN Helps People with Bladder Cancer Make Informed Treatment Decisions

In In The News by Barbara Jacoby

New NCCN Guidelines for Patients: Bladder Cancer explains the lengthy surveillance process that follows active treatment for the sixth most-common cancer in the United States. The treatment landscape for bladder cancer has changed dramatically over the past few years. Despite being the sixth most common cancer in the United States, and fourth most common for men—impacting an estimated 81,000 Americans …

View Post

Pangea® Laboratory to License Bladder CARE™ Technology from Zymo Research

In Clinical Studies News by Barbara Jacoby

Source: Pangea Laboratory From: prnewswire.com Non-invasive, epigenetic-based test for bladder cancer detection Pangea® Laboratory announced today the licensing of a new urine-based Laboratory Developed Test (LDT) for bladder cancer detection. Commercialized and sold under the name Bladder CARE™, the test is non-invasive, cost-effective and epigenetic-based. Urine samples for the Bladder CARE™ test can be collected comfortably at home or at …

View Post

Cancer spread could be stopped by common cold medicine, scientists discover

In In The News by Barbara Jacoby

By: Tom Embury-Dennis From: independent.co.uk A drug used to treat the common cold could be used to stop the spread of bladder cancer, a study has found. Researchers in Japan found that a nonsteroid anti-inflammatory drug supressed the spread of the cancer in mice and also reduced its resistance to chemotherapy. The results raise hopes of a cure for a disease …

View Post

Nearly 1 in 12 patients with a common cancer develop a second, unrelated malignancy

In In The News by Barbara Jacoby

By: Kim Irwin From: ucla.edu Reported by: Redington Life Sciences News UCLA researchers have identified the incidence and long-term outcomes of patients who develop second, unrelated cancers, resulting in a data set that they say sheds new light on the way cancer survivors may need to be monitored post-disease. The researchers identified more than 2.1 million patients from the Surveillance, …